Open AccessMutant TP53 modulates metastasis of triple negative breast cancer through adenosine A2b receptor signaling
Author(s) -
Eisuke Horigome,
Michiru Fujieda,
Tadashi Handa,
Ayaka Katayama,
Masashi Ito,
Ami Ichihara,
Daiki Tanaka,
Navchaa Gombodorj,
Shinji Yoshiyama,
Arito Yamane,
Keiichi Yamada,
Jun Horiguchi,
Kazuo Shinozuka,
Tetsunari Oyama,
Masahiko Nishiyama,
Susumu Rokudai
Publication year - 2018
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.26177
Subject(s) - triple negative breast cancer , breast cancer , cancer research , mutant , medicine , metastasis , adenosine , signal transduction , cancer , receptor , breast cancer metastasis , biology , oncology , cancer metastasis , microbiology and biotechnology , gene , genetics
The identification of genes with synthetic lethality in the context of mutant TP53 is a promising strategy for the treatment of basal-like triple negative breast cancer (TNBC). This study investigated regulators of mutant TP53 (R248Q) in basal-like TNBC and their impact on tumorigenesis.